Comments
Dr Reddy’s Laboratories has said a German regulatory authority has allowed the company’s Visakhapatnam-based plant to restart production for the European Union market.
“The corrective and preventive action plan (CAPA) submitted by us has been accepted by the regulator. Consequently, the regulator has permitted production to start again from this facility for the EU market,” Dr Reddy’s Laboratories said in a regulatory filing today.
However, the regulator will re-inspect the facility by the end of 2018, it added.
In September, a German regulatory authority had issued six major observations against the Hyderabad-based drug firm's formulations unit at Visakhapatnam in Andhra Pradesh after an inspection.
The company, however, did not elaborate on the observations which were made by the regulator related to violation of good manufacturing practises (GMP).
Dr Reddy’s shares ended up by 0.45 per cent at Rs 2,286.35 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.